VECT

PRESS RELEASE Memo Therapeutics AG appoints Paul Carter as Chairperson Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV Extensive public and private market experience following executive positions in numerous biopharma companies                  Schlieren / Zurich, Switzerland, 8 July, 2024 – Memo Therapeutics AG (or "MTx"), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as Chairperson of the Board of Directors. Paul has had an extensive executive career in the biopharma space, with commercial a

enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the election of Paul Hastings and Wouter Joustra as new members of its Board of Directors at the Company's 2024 annual meeting of shareholders. Shareholders also reelected incumbent director Lota Zoth. Each will serve a three-year term expiring at the 2027 annual meeting of shareholders. enGene's Board is now comprised of seven members including Richard Glickman (Chairman), Gerald Brunk, Jasper Bos, and Jason Hanson. "We are pleased to welcome Paul and Wouter to our Board of

STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.Hans Schikan has been a member of the Board since 2018 and is a leader in rare disease drug development and strategy. He was previously CEO of Prosensa (NASDAQ:RNA), a company developing therapies for rare diseas

SC 13G/A - VectivBio Holding AG (0001836379) (Subject)

EFFECT - VectivBio Holding AG (0001836379) (Filer)

EFFECT - VectivBio Holding AG (0001836379) (Filer)

EFFECT - VectivBio Holding AG (0001836379) (Filer)

POS AM - VectivBio Holding AG (0001836379) (Filer)

POS AM - VectivBio Holding AG (0001836379) (Filer)

POS AM - VectivBio Holding AG (0001836379) (Filer)

S-8 POS - VectivBio Holding AG (0001836379) (Filer)

S-8 POS - VectivBio Holding AG (0001836379) (Filer)

6-K - VectivBio Holding AG (0001836379) (Filer)

25 - VectivBio Holding AG (0001836379) (Filer)

SC 13D - VectivBio Holding AG (0001836379) (Subject)

Santarelli is a Proven Leader with a Track Record of Building Successful Biotech Companies Alentis Therapeutics ("Alentis"), a clinical-stage biotechnology company developing treatments for organ fibrosis and Claudin-1 positive tumors, announced today the appointment of Dr. Luca Santarelli as the Chair of its Board of Directors. Rafaèle Tordjman, former chair of Alentis, will remain on Alentis' board. "I'm pleased to welcome Luca as chair of our board. His experience as a serial biotech entrepreneur and Alentis board member since 2021 are of great value to our board and company," said Dr. Roberto Iacone, Chief Executive Officer of Alentis. "I very much want to thank Rafaèle for her trem

SC 14D9/A - VectivBio Holding AG (0001836379) (Subject)

6-K - VectivBio Holding AG (0001836379) (Filer)

SC TO-T/A - VectivBio Holding AG (0001836379) (Subject)

Ironwood Pharmaceuticals, Inc. ("Ironwood") (NASDAQ:IRWD), a GI-focused healthcare company, and VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a global clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastrointestinal conditions, today announced the successful completion of the tender offer to purchase the outstanding ordinary shares of VectivBio (the "Shares") for $17.00 per share in cash (the "Tender Offer"). The Depositary for the Tender Offer has advised Ironwood and VectivBio that at the end of the offering period, 59,287,753 Shares had been tendered and not withdrawn pursuant to the Tender Offer and it has received commitments

SC TO-T/A - VectivBio Holding AG (0001836379) (Subject)

SC 14D9/A - VectivBio Holding AG (0001836379) (Subject)

6-K - VectivBio Holding AG (0001836379) (Filer)

BASEL, Switzerland, June 26, 2023 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a global clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastrointestinal conditions, announced that today's extraordinary general meeting approved each of the proposals of the Board of Directors, which satisfied one of the pending conditions to consummating the tender offer by Ironwood Pharmaceuticals, Inc. ("Ironwood") to acquire all of VectivBio's outstanding registered ordinary shares for $17.00 per share in cash (subject to deduction for any applicable withholding taxes). Consummation of the tender offer remains subject to the t

SC 14D9/A - VectivBio Holding AG (0001836379) (Subject)